ClinVar Miner

Submissions for variant NM_031885.5(BBS2):c.1237C>T (p.Arg413Ter)

gnomAD frequency: 0.00003  dbSNP: rs147030232
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 12
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000411465 SCV000486380 likely pathogenic Bardet-Biedl syndrome 2 2016-11-02 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV000762966 SCV000893407 pathogenic Bardet-Biedl syndrome 2; Retinitis pigmentosa 74 2021-10-16 criteria provided, single submitter clinical testing
Centre for Genomic Medicine, Manchester, Central Manchester University Hospitals RCV000411465 SCV001156386 pathogenic Bardet-Biedl syndrome 2 2019-02-01 criteria provided, single submitter clinical testing
Invitae RCV001069542 SCV001234716 pathogenic Bardet-Biedl syndrome 2024-01-29 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Arg413*) in the BBS2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BBS2 are known to be pathogenic (PMID: 11285252, 20177705, 24608809, 26518167). This variant is present in population databases (rs147030232, gnomAD 0.005%). This premature translational stop signal has been observed in individuals with Bardet-Biedl syndrome (PMID: 12920096, 21642631, 29588463). ClinVar contains an entry for this variant (Variation ID: 370943). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001069542 SCV001361413 pathogenic Bardet-Biedl syndrome 2019-08-30 criteria provided, single submitter clinical testing Variant summary: BBS2 c.1237C>T (p.Arg413X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 2e-05 in 251474 control chromosomes (gnomAD). c.1237C>T has been reported in the literature (including homozygous occurrences) in multiple individuals and families affected with Bardet-Biedl Syndrome (e.g. Fauser_2003, Chen_2011, Sanchez-Navarro_2018, Liu_2015). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and classified the variant as pathogenic (1x) or likely pathogenic (1x). Based on the evidence outlined above, the variant was classified as pathogenic.
GeneDx RCV001571149 SCV001795568 pathogenic not provided 2019-06-07 criteria provided, single submitter clinical testing Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease This variant is associated with the following publications: (PMID: 31960602, 30293640, 21642631, 12920096, 25525159, 21052717, 15224652)
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute RCV000411465 SCV002557565 pathogenic Bardet-Biedl syndrome 2 2022-02-02 criteria provided, single submitter clinical testing Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with Bardet-Biedl syndrome 2 (MIM#615981) and retinitis pigmentosa 74 (MIM#616562). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD <0.01 for a recessive condition (v2: 6 heterozygotes, 0 homozygotes). (SP) 0701 - Other NMD-predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity (Decipher; PMID: 31283077). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been classified as likely pathogenic or pathogenic by clinical diagnostic laboratories and has been reported as homozygous or compound heterozygous in individuals with Bardet-Biedl syndrome 2 or retinitis pigmentosa (ClinVar; PMIDs: 19797195, 21344540, 26325687, 29588463, 31960602). (SP) 1205 - This variant has been shown to be maternally inherited (by trio analysis). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign
Baylor Genetics RCV000411465 SCV004213983 pathogenic Bardet-Biedl syndrome 2 2023-10-22 criteria provided, single submitter clinical testing
Dept Of Ophthalmology, Nagoya University RCV003889878 SCV004705058 pathogenic Retinal dystrophy 2023-10-01 criteria provided, single submitter research
PreventionGenetics, part of Exact Sciences RCV004530497 SCV004743069 pathogenic BBS2-related disorder 2024-02-06 criteria provided, single submitter clinical testing The BBS2 c.1237C>T variant is predicted to result in premature protein termination (p.Arg413*). This variant has previously been found in the compound heterozygous and homozygous states in individuals with autosomal recessive Bardet-Biedl syndrome and retinitis pigmentosa (Janssen et al. 2011. PubMed ID: 21052717; Dan et al. 2020. PubMed ID: 31960602; Liu et al. 2015. PubMed ID: 25611614). This variant is reported in 0.0050% of alleles in individuals of East Asian descent in gnomAD. Nonsense variants in BBS2 are expected to be pathogenic. This variant is interpreted as pathogenic.
Natera, Inc. RCV000411465 SCV001457436 pathogenic Bardet-Biedl syndrome 2 2020-09-16 no assertion criteria provided clinical testing
Genomics England Pilot Project, Genomics England RCV000411465 SCV001760373 likely pathogenic Bardet-Biedl syndrome 2 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.